Related Experiment Video

Updated: Jul 15, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: Current Evidence and Future Opportunities

Sho Suzuki1,2, Takeshi Kitai1, John Skoularigis3

  • 1Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan.

Journal of Personalized Medicine
|September 28, 2023
PubMed

Insights

Catheter ablation (CA) shows promise for managing atrial fibrillation (AF) in heart failure (HF) patients, potentially improving outcomes. This review examines the evidence, benefits, risks, and influencing factors of CA for AF in HF.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Research

Background:

  • Atrial fibrillation (AF) and heart failure (HF) are prevalent, increasing cardiac disorders with poor prognosis.
  • These conditions frequently coexist and can influence each other's development and progression.
  • AF significantly increases adverse outcomes in HF patients, including mortality, hospitalization, and stroke.

Purpose of the Study:

  • To review current evidence on the efficacy of catheter ablation (CA) for managing AF in patients with HF.
  • To discuss the potential benefits and risks associated with CA in this population.
  • To explore factors influencing treatment outcomes and identify knowledge gaps.

Main Methods:

  • Comprehensive literature review of scientific evidence.
  • Analysis of studies evaluating catheter ablation for AF in heart failure patients.
  • Discussion of clinical trial data and observational studies.

Main Results:

  • Catheter ablation is emerging as a promising therapeutic option for AF in HF patients.
  • Evidence suggests potential benefits in managing AF and improving outcomes in this complex group.
  • Further research is needed to fully elucidate the role and optimize CA strategies.

Conclusions:

  • Catheter ablation is a viable and promising treatment for atrial fibrillation in heart failure patients.
  • Understanding benefits, risks, and influencing factors is crucial for optimal patient selection and management.
  • Continued research is essential to refine CA techniques and confirm long-term efficacy.

Keywords:
atrial fibrillationcatheter ablationheart failurereview

More Related Videos

Robotic Ablation of Atrial Fibrillation11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.7K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16